EntreMed to Present at Needham Biotechnology Conference
May 19, 2005
ROCKVILLE, MD, May 19—EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the Fourth Annual Needham Biotechnology Conference, to be held at the New York Palace Hotel, May 25-26, 2005. Mr. Burns’ presentation is scheduled for Thursday, May 26, 2005 at 1:00 p.m. (local time).
Mr. Burns’ live presentation will be web cast and can be accessed through the Company’s web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
CASI Pharmaceuticals, Inc.